Pass-Through Royalties. In consideration for the licenses granted herein: (a) Rigel agrees to pay any amounts which CG is required to pay to Rockefeller University under the CG License as a result of CG's grant to Rigel of license rights to CG Patents or CG Know-How to Rigel or the exercise of the license rights granted by CG under the CG License. (b) Rigel agrees to pay CG (i) [ * ] for the license granted to Rigel hereunder to CG Patents related to the [ * ] cell lines, and (ii) [ * ] for each sublicense granted by Rigel under this Agreement. (c) CG agrees that in the event CG exercises its option to obtain a license pursuant to Section 2.2(a) above, CG will pay any amounts which Rigel is required to pay to Stanford University under the Rigel Licesne as a result of ▇▇▇▇▇'▇ ▇▇▇▇▇ to CG of license rights to Rigel Biolgoical Material or Rigel Know-How to CG or the exercise of the license rights granted by Rigel under the Rigel License. It is understood that unless and until CG obtains such license rights from ▇▇▇▇▇, ▇▇ shall not be obligated to pay to Rigel or to Stanford University any amounts that Rigel is required to pay to Stanford University under the Rigel License.
Appears in 2 contracts
Sources: License and Research Agreement (Rigel Pharmaceuticals Inc), License and Research Agreement (Rigel Pharmaceuticals Inc)
Pass-Through Royalties. In consideration for the licenses granted herein:
(a) Rigel agrees to pay any amounts which CG is required to pay to Rockefeller University [ * ] under the CG License as a result of CG's grant to Rigel of license rights to CG Patents or CG Know-How to Rigel or the exercise of the license rights granted by CG under the CG License.
(b) Rigel agrees to pay CG (i) [ * ] for the license granted to Rigel hereunder to CG Patents related to the [ * ] cell lines, and (ii) [ * ] for each sublicense granted by Rigel under this Agreement.
(c) CG agrees that in the event CG exercises its option to obtain a license pursuant to Section 2.2(a) above, CG will pay any amounts which Rigel is required to pay to Stanford University under the Rigel Licesne as a result of ▇▇▇▇▇'▇ ▇▇▇▇▇ to CG of license rights to Rigel Biolgoical Material or Rigel Know-How to CG or the exercise of the license rights granted by Rigel under the Rigel License. It is understood that unless and until CG obtains such license rights from ▇▇▇▇▇, ▇▇ shall not be obligated to pay to Rigel or to Stanford University any amounts that Rigel is required to pay to Stanford University under the Rigel License.
Appears in 1 contract
Sources: License and Research Agreement (Rigel Pharmaceuticals Inc)
Pass-Through Royalties. In consideration for the licenses granted herein:
(a) Rigel agrees to pay any amounts which CG is required to pay to Rockefeller University under the CG License as a result of CG's grant to Rigel of license rights to CG Patents or CG Know-How to Rigel or the exercise of the license rights granted by CG under the CG License.
(b) Rigel agrees to pay CG (i) [ * [*] for the license granted to Rigel hereunder to the CG Patents related to the [ * [*] cell lines, and (ii) [ * [*] for each sublicense granted by Rigel under this Agreement.
(c) CG agrees that in the event CG exercises its option to obtain a license pursuant to Section 2.2(a) above, CG will pay any amounts which Rigel is required to pay to Stanford University under the Rigel Licesne License as a result of ▇▇▇▇▇'▇ ▇▇▇▇▇ to CG of license rights to Rigel Biolgoical Material Biological Materials or Rigel Know-How to CG or the exercise of the license rights granted by Rigel under the Rigel License. It is understood that unless and until CG obtains such license rights from ▇▇▇▇▇, ▇▇ shall not be obligated to pay to Rigel or to Stanford University any amounts that Rigel is required to pay to Stanford University under the Rigel License.
Appears in 1 contract
Sources: License and Research Agreement (Rigel Pharmaceuticals Inc)
Pass-Through Royalties. In consideration for the licenses granted herein:
(a) Rigel agrees to pay any amounts which CG is required to pay to Rockefeller University under the CG License as a result of CG's grant to Rigel of license rights to CG Patents or CG Know-How to Rigel or the exercise of the license rights granted by CG under the CG License.
(b) Rigel agrees to pay CG (i) [ * ] for the license granted to Rigel hereunder to CG Patents related to the [ * ] cell lines, and (ii) [ * ] for each sublicense granted by Rigel under this Agreement.
(c) CG agrees that in the event CG exercises its option to obtain a license pursuant to Section 2.2(a) above, CG will pay any amounts which Rigel is required to pay to Stanford University under the Rigel Licesne License as a result of ▇▇▇▇▇'▇ ▇▇▇▇▇ to CG of license rights to Rigel Biolgoical Biological Material or Rigel Know-How to CG or the exercise of the license rights granted by Rigel under the Rigel License. It is understood that unless and until CG obtains such license rights from ▇▇▇▇▇, ▇▇ shall not be obligated to pay to Rigel or to Stanford University any amounts that Rigel is required to pay to Stanford University under the Rigel License.
Appears in 1 contract
Sources: License and Research Agreement (Rigel Pharmaceuticals Inc)
Pass-Through Royalties. In consideration for the licenses granted herein:
(a) Rigel agrees to pay any amounts which CG is required to pay to Rockefeller University under the CG License as a result of CG's ’s grant to Rigel of license rights to CG Patents or CG Know-How to Rigel or the exercise of the license rights granted by CG under the CG License.
(b) Rigel agrees to pay CG (i) [ * ] for the license granted to Rigel hereunder to the CG Patents related to the [ * ] cell lines, and (ii) [ * ] for each sublicense granted by Rigel under this Agreement.
(c) CG agrees that in the event CG exercises its option to obtain a license pursuant to Section 2.2(a) above, CG will pay any amounts which Rigel is required to pay to Stanford University under the Rigel Licesne License as a result of ▇▇▇▇▇'’▇ ▇▇▇▇▇ to CG of license rights to Rigel Biolgoical Material Biological Materials or Rigel Know-How to CG or the exercise of the license rights granted by Rigel under the Rigel License. It is understood that unless and until CG obtains such license rights from ▇▇▇▇▇, ▇▇ shall not be obligated to pay to Rigel or to Stanford University any amounts that Rigel is required to pay to Stanford University under the Rigel License.
Appears in 1 contract
Sources: License and Research Agreement (Rigel Pharmaceuticals Inc)